Table 2 Clinical, pathologic, and treatment characteristics
Age (years) | |
Mean | 58.2 |
Median | 57 |
Range | 26–84 |
Gender | |
F | 30 (37 %) |
M | 51 (63 %) |
Performance status (KPS) | |
81–100 | 71(88 %) |
≤80 | 10 (12 %) |
Cardiovascular disease | |
No | 74 (91 %) |
Yes | 7 (9 %) |
Diabetes | |
No | 72 (89 %) |
Yes | 9 (11 %) |
Smoking history | |
No | 57 (70 %) |
Yes | 24 (30 %) |
Stage | |
I | 20 (25 %) |
II | 10 (12 %) |
III | 51 (63 %) |
Size | |
<10 cm | 38 (47 %) |
≥10 cm | 43 (53 %) |
Location | |
Proximal lower extremity | 69 (85 %) |
Buttock | 8 (10 %) |
Hip/pelvis | 4 (5 %) |
Grade | |
Low | 23 (28 %) |
Intermediate | 4 (5 %) |
High | 54 (67 %) |
Histology | |
Undifferentiated | 10 (12 %) |
Liposarcoma/leiomyosarcoma | 31 (38 %) |
Myxofibrosarcoma | 11 (14 %) |
Synovial | 4 (5 %) |
Spindle cell | 13 (16 %) |
Other | 12(15 %) |
Neoadjuvant chemotherapy | |
No | 25 (31 %) |
Yes | 56 (69 %) |
Timing of RT | |
No RT | 8 (10 %) |
Preoperative RT | 70 (86 %) |
Post-operative RT | 3 (4 %) |
Flap reconstruction | |
No | 50 (62 %) |
Yes | 31(38 %) |